CLINICAL TRIALS PROFILE FOR LUNESTA

All Clinical Trials for LUNESTA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00120250 ↗	Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder	Completed	Massachusetts General Hospital	Phase 4	2005-06-01	The purpose of this study is to obtain data investigating the safety and efficacy of eszopiclone for the treatment of post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with eszopiclone treatment on neuroendocrine correlates of PTSD. The investigators hypothesize that eszopiclone will be significantly more effective than placebo and well tolerated for PTSD-related sleep disturbance, improvement in sleep will be associated with improvement in overall PTSD symptoms, and patients with PTSD-related sleep disturbances will have abnormal levels of stress hormones.
NCT00235508 ↗	Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder	Completed	Sunovion	Phase 4	2005-06-01	To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will receive an approved anxiolytic agent and will be randomized to nightly therapy with either eszopiclone or placebo.
NCT00283790 ↗	Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo	Completed	Sanofi	Phase 4	2006-01-01	Investigation of Psychomotor and Cognitive Residual Effects of Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopiclone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Flurazepam 30 mg as an External Comparator
NCT00352144 ↗	6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia	Completed	Sunovion	Phase 3	2003-10-01	To evaluate the long-term efficacy of eszopiclone administered for up to 6 months in subjects with primary insomnia on subjective sleep measures, compared to placebo.
NCT00365261 ↗	Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer	Completed	University of California, San Diego	Phase 4	2006-09-01	To assess the effectiveness of Lunesta on cancer patients who have received chemotherapy and who require patient controlled analgesia (PCA), specifically to assess whether Lunesta will: - improve sleep thereby decreasing need for opiates via PCA - improve sleep thereby decreasing pain by self report - improve sleep thereby decreasing fatigue by self report

Clinical Trial Conditions for LUNESTA

Condition Name

Condition Name for LUNESTA
Intervention	Trials
Insomnia	17
Primary Insomnia	7
Obstructive Sleep Apnea	6
Healthy	3

Condition MeSH

Condition MeSH for LUNESTA
Intervention	Trials
Sleep Initiation and Maintenance Disorders	27
Sleep Apnea, Obstructive	8
Sleep Apnea Syndromes	8
Sleep Wake Disorders	6

Clinical Trial Locations for LUNESTA

Trials by Country

Trials by Country for LUNESTA
Location	Trials
United States	159
United Kingdom	5
India	3
Ukraine	2
France	1

Trials by US State

Trials by US State for LUNESTA
Location	Trials
Massachusetts	15
California	11
Ohio	7
Illinois	6
North Carolina	6

Clinical Trial Progress for LUNESTA

Clinical Trial Phase

Clinical Trial Phase for LUNESTA
Clinical Trial Phase	Trials
Phase 4	20
Phase 3	6
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for LUNESTA
Clinical Trial Phase	Trials
Completed	37
Recruiting	3
Terminated	3

Clinical Trial Sponsors for LUNESTA

Sponsor Name

Sponsor Name for LUNESTA
Sponsor	Trials
Sunovion	27
Massachusetts General Hospital	5
University of California, San Diego	5

Sponsor Type

Sponsor Type for LUNESTA
Sponsor	Trials
Other	38
Industry	33
U.S. Fed	4